Field Medical Secures $40 Million Series A Financing to Advance Pulsed Field Ablation for Ventricular Tachycardia
• Field Medical Inc. has raised $40 million in Series A financing to advance its FieldForce™ Ablation System, which delivers instantaneous cardiac ablation therapy in a fraction of a second.
• The funding will support completion of two pilot studies (VCAS for ventricular tachycardia and Field PULSE for atrial fibrillation) and preparation for the pivotal VERITAS trial focused on VT.
• The company's technology received FDA Breakthrough Device Designation in 2024, addressing a significant market with VT affecting over 6 million people in the US and Europe.
Medtronic's Affera System Receives FDA Approval for Ventricular Tachycardia Treatment Study
• Medtronic gains FDA approval for an early feasibility study of the Affera Mapping and Ablation System with Sphere-9 Catheter for sustained ventricular tachycardia (VT).
• The study will assess the safety and effectiveness of the Affera system in ablating targeted VT in patients with post-myocardial infarction scarring.
• The Affera system combines pulsed field (PF) and radiofrequency (RF) ablation with high-density mapping for cardiac electrophysiology ablation procedures.
• The trial's primary endpoints include monitoring device-related adverse events and evaluating the acute success of VT ablation over a six-month follow-up.
© Copyright 2025. All Rights Reserved by MedPath